Bristol-Myers Squibb Co vs Rent the Runway Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Rent the Runway Inc trades at $3.59 (market cap $122.65M). The key difference: Bristol-Myers Squibb Co is far larger — about 1059.4× Rent the Runway Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals.
| BMY | RENT | |
|---|---|---|
Market Cap | $129.94B | $122.65M |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $9.39 |
52-Week Low | $42.60 | $3.01 |
Enterprise Value | $163.92B | $282.75M |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Rent the Runway (RENT) trades at $3.70, up 1.65% with a bullish technical signal. The company shows improving fundamentals with Q1 2026 revenue growth of 29.2% to $89.9M and narrowing losses. Despite negative equity of -$182.5M, valuation metrics appear attractive with P/E of 0.48 and P/S of 0.2. Recent leadership transition with Teri Bariquit as interim CEO brings fresh perspective to the subscription fashion platform.
The outlook remains cautiously optimistic with analyst consensus leaning buy (42%) though profitability challenges persist. Key opportunities include subscriber growth and margin improvement, while risks involve high debt load and competitive pressure. The stock offers speculative upside if the company can achieve projected 2026 profitability of $30M net income.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →